MSLN and metastatic malignant neoplasm in the lymph nodes: In the WCMC cohort, comprising castration-resistant tumors, elevated MSLN expression was observed in 6.6% (1/15) of the CRPC-Neuroendocrine cases, and in 3% (1/34) of the CRPC-adeno cases, this later corresponding to one case of lymph node metastasis.